Developing and validating SARS‐CoV‐2 assays for nonhuman primate surveillance

Introduction In early 2020, the California National Primate Research Center implemented surveillance to address the threat of SARS‐CoV‐2 infection in its nonhuman primate colony. Materials/Methods To detect antiviral antibodies, multi‐antigen assays were developed and validated on enzyme immunoassay...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of medical primatology Ročník 51; číslo 5; s. 264 - 269
Hlavní autoři: Yee, JoAnn, Carpenter, Amanda, Nham, Peter, Halley, Bryson, Van Rompay, Koen K. A., Roberts, Jeffrey
Médium: Journal Article
Jazyk:angličtina
Vydáno: Denmark Wiley Subscription Services, Inc 01.10.2022
John Wiley and Sons Inc
Témata:
Animals
Antibodies, Viral
antibody
Antigens
Antiviral drugs
COVID-19 - diagnosis
diagnostic testing algorithm
Enzyme immunoassay
Laboratories
Microspheres
Nucleocapsids
Original
RNA, Viral
RT‐PCR
SARS-CoV-2
Sensitivity and Specificity
Severe acute respiratory syndrome coronavirus 2
Surveillance
RT-PCR
diagnostic testing algorithm
antibody
ISSN:0047-2565, 1600-0684, 1600-0684
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Introduction In early 2020, the California National Primate Research Center implemented surveillance to address the threat of SARS‐CoV‐2 infection in its nonhuman primate colony. Materials/Methods To detect antiviral antibodies, multi‐antigen assays were developed and validated on enzyme immunoassay and multiplex microbead immunofluorescent assay (MMIA) platforms. To detect viral RNA, RT‐PCR was also performed. Results/Conclusion Using a 4plex, antibody was identified in 16/16 experimentally infected animals; and specificity for spike, nucleocapsid, receptor binding domain, and whole virus antigens was 95.2%, 93.8%, 94.3%, and 97.1%, respectively on surveillance samples. Six laboratories compared this MMIA favorably with nine additional laboratory‐developed or commercially available assays. Using a screen and confirm algorithm, 141 of the last 2441 surveillance samples were screen‐reactive requiring confirmatory testing. Although 35 samples were reactive to either nucleocapsid or spike; none were reactive to both. Over 20 000 animals have been tested and no spontaneous infections have so far been confirmed across the NIH sponsored National Primate Research Centers.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0047-2565
1600-0684
1600-0684
DOI:10.1111/jmp.12604